Literature DB >> 8888066

The antiglucocorticoid action of mifepristone.

M K Agarwai1.   

Abstract

Glucocorticoid hormones influence the physiological activity of almost all cell types in the mammal. This is accomplished via a soluble receptor that, in the presence of an appropriate steroid, modifies the activity of RNA polymerase by binding to the site where different factors assemble for the initiation of cell transcription. The development of antiglucocorticoids has permitted the molecular elucidation of a number of underlying events. Contrary to the classical view, it is now clear that the affinity, stability and activability of the glucocorticoid receptor in the presence of a steroid are cell- and/or tissue-dependent events. The antiglucocorticoid RU 38486 can even activate transcription by binding to sites distinct from those that process transactivation by the agonist. Furthermore, glucocorticoids can sometimes activate the mineralocorticoid receptor, whereas mineralocorticoids can bind the glucocorticoid receptor. Since mifepristone is devoid of adverse toxicity, it has been used for the paraclinical diagnosis of the hypothalamus-pituitary-adrenal axis in normal volunteers, subjects with disorders of the behaviour, and the treatment of Cushing's disease. However, the whole spectrum of cell-specific processes that are antagonized by RU 38486 suggests wide ranging possibilities in the eventual application of antigluco-corticoids.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8888066     DOI: 10.1016/0163-7258(96)00016-2

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  9 in total

1.  Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system.

Authors:  Carola Förster; Christine Silwedel; Nikola Golenhofen; Malgorzata Burek; Silke Kietz; Joachim Mankertz; Detlev Drenckhahn
Journal:  J Physiol       Date:  2005-03-24       Impact factor: 5.182

2.  RU486 blocks the anti-inflammatory effects of exercise in a murine model of allergen-induced pulmonary inflammation.

Authors:  Amy Pastva; Kim Estell; Trenton R Schoeb; Lisa M Schwiebert
Journal:  Brain Behav Immun       Date:  2005-09       Impact factor: 7.217

3.  Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND.

Authors:  Carola Förster; Timo Kahles; Silke Kietz; Detlev Drenckhahn
Journal:  J Physiol       Date:  2007-02-22       Impact factor: 5.182

4.  Multiple Components of Protein Homeostasis Pathway Can Be Targeted to Produce Drug Synergies with VCP Inhibitors in Ovarian Cancer.

Authors:  Prabhakar Bastola; Gary S Leiserowitz; Jeremy Chien
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

5.  Glucocorticoid mechanisms may contribute to ECT-induced retrograde amnesia.

Authors:  Nandakumar Nagaraja; Chittaranjan Andrade; Suresh Sudha; Nagendra Madan Singh; J Suresh Chandra; B V Venkataraman
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

Review 6.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

7.  Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.

Authors:  Morito Kurata; Susan K Rathe; Natashay J Bailey; Natalie K Aumann; Justine M Jones; G Willemijn Veldhuijzen; Branden S Moriarity; David A Largaespada
Journal:  Sci Rep       Date:  2016-11-03       Impact factor: 4.379

8.  Late gestation modulation of fetal glucocorticoid effects requires the receptor for leukemia inhibitory factor: an observational study.

Authors:  Carol B Ware; Angelique M Nelson; Denny Liggitt
Journal:  Reprod Biol Endocrinol       Date:  2003-05-16       Impact factor: 5.211

9.  Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression.

Authors:  Rong Liu; Peiguo Shi; Zhi Nie; Huichun Liang; Zhongmei Zhou; Wenlin Chen; Haijun Chen; Chao Dong; Runxiang Yang; Suling Liu; Ceshi Chen
Journal:  Theranostics       Date:  2016-02-13       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.